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1. INTRODUCTION {#dom13079-sec-0001}
===============

By inhibiting the degradation of glucagon‐like peptide‐1, dipeptidyl peptidase‐4 (DPP‐4) inhibitors promote insulin secretion and suppress glucagon secretion. Because the mode of action is dependent on the glucose concentration, DPP‐4 inhibitors have a low risk of causing hypoglycaemia.[1](#dom13079-bib-0001){ref-type="ref"} Sodium glucose co‐transporter 2 (SGLT2) inhibitors reduce urinary glucose reabsorption by inhibiting SGLT2, lower plasma glucose in an insulin‐independent manner and help to alleviate glucose toxicity. They are also expected to improve insulin resistance by alleviating glucose toxicity and decreasing body weight.[2](#dom13079-bib-0002){ref-type="ref"}, [3](#dom13079-bib-0003){ref-type="ref"} The independent mechanisms of action of these drugs and the low risk of hypoglycaemia provide support for combination therapy as a therapeutic option. Indeed, prior studies have demonstrated that combination therapy with an SGLT2 inhibitor and a DPP‐4 inhibitor was effective and well tolerated.[4](#dom13079-bib-0004){ref-type="ref"}, [5](#dom13079-bib-0005){ref-type="ref"}, [6](#dom13079-bib-0006){ref-type="ref"}, [7](#dom13079-bib-0007){ref-type="ref"}, [8](#dom13079-bib-0008){ref-type="ref"}

Consequently, fixed‐dose combinations of a DPP‐4 inhibitor and an SGLT2 inhibitor are anticipated, and 2 fixed‐dose combination drugs of a DPP‐4 inhibitor and an SGLT2 inhibitor, linagliptin/empagliflozin and saxagliptin/dapagliflozin, have been launched in the USA and Europe, respectively.[8](#dom13079-bib-0008){ref-type="ref"}, [9](#dom13079-bib-0009){ref-type="ref"}, [10](#dom13079-bib-0010){ref-type="ref"} No fixed‐dose combinations of a DPP‐4 inhibitor and an SGLT2 inhibitor have been approved in Japan.

In this context, the development of a fixed‐dose combination of teneligliptin, a DPP‐4 inhibitor, and canagliflozin, an SGLT2 inhibitor, has proceeded. A study examining the efficacy and safety of adding canagliflozin to ongoing teneligliptin therapy in Japanese patients has also been conducted (NCT02354235, NCT02220907), and the results have been reported previously.[11](#dom13079-bib-0011){ref-type="ref"}, [12](#dom13079-bib-0012){ref-type="ref"} In this study, we examined the efficacy of teneligliptin added to canagliflozin monotherapy in Japanese patients with poorly controlled T2DM as part of the development programme. This is the first clinical trial evaluating the efficacy and safety of adding a DPP‐4 inhibitor to ongoing SGLT2 inhibitor treatment in Japanese T2DM patients. Therefore, this trial provides important information because there are differences in the pathology of T2DM between Japanese and Caucasian patients.[13](#dom13079-bib-0013){ref-type="ref"}

2. METHODS {#dom13079-sec-0002}
==========

Details of the patient inclusion/exclusion criteria, secondary efficacy endpoints and statistical analyses are provided in [Appendix S1](#dom13079-supitem-0001){ref-type="supplementary-material"} (Methods). In brief, Japanese patients with T2DM and inadequate glycaemic control despite canagliflozin monotherapy in conjunction with diet and exercise therapy were eligible, provided they had undergone canagliflozin monotherapy for ≥8 weeks before the run‐in period.

2.1. Ethics {#dom13079-sec-0003}
-----------

This trial complied with the Declaration of Helsinki, the Japanese Law for Ensuring the Quality, Efficacy, and Safety of Drugs and Medical Devices, Good Clinical Practice, and the approved study protocol. The procedures were approved by institutional review boards at all participating institutions, which are listed in [Appendix S1](#dom13079-supitem-0001){ref-type="supplementary-material"}. The trial was registered at [ClinicalTrials.gov](http://clinicaltrials.gov) (NCT02354222).

2.2. Study design and treatments {#dom13079-sec-0004}
--------------------------------

The study comprised a 4‐week run‐in period, a 24‐week double‐blind treatment period, and a 2‐week post‐treatment observation period (Figure [S1](#dom13079-supitem-0002){ref-type="supplementary-material"}). All patients received canagliflozin at a dose of 100 mg (the approved dose in Japan) once daily before breakfast during the run‐in period, treatment period and post‐treatment observation period. At the start of the treatment period, patients were randomized in a 1:1 manner to receive placebo (C + P group) or teneligliptin (C + T group) at a dose of 20 mg once daily before breakfast. Randomization was performed using the permuted block method. Diet and exercise therapy was to continue unchanged throughout the trial.

2.3. Primary efficacy and safety endpoints {#dom13079-sec-0005}
------------------------------------------

The primary efficacy endpoint was the change in HbA1c from baseline to the end of the treatment period. The safety of C + T and C + P was assessed in terms of adverse events (AEs), hypoglycaemia, laboratory variables (haematology, blood biochemistry and urinalysis), electrocardiography and vital signs. AEs were evaluated in terms of their seriousness and relationship to the study drugs. AEs and drug‐related AEs were classified according to the System Organ Class and Preferred Term using the MedDRA version 18.1J.

3. RESULTS {#dom13079-sec-0006}
==========

3.1. Patient disposition and baseline characteristics {#dom13079-sec-0007}
-----------------------------------------------------

A total of 213 patients were initially enrolled, of whom 59 discontinued before the treatment period (Figure [S2](#dom13079-supitem-0003){ref-type="supplementary-material"}); therefore, 154 patients were randomized, with 77 patients per group. Patient characteristics are shown in [Table S1](#dom13079-supitem-0001){ref-type="supplementary-material"}, [Appendix S1](#dom13079-supitem-0001){ref-type="supplementary-material"}.

3.2. Efficacy variables {#dom13079-sec-0008}
-----------------------

The primary endpoint, the LS mean ± SE (baseline value as covariate) change in HbA1c from baseline to Week 24 (LOCF) was 0.00% ± 0.08% and −0.94% ± 0.08% in the C + P and C + T groups, respectively, with a significant between‐group difference of −0.94% ± 0.11% (*P* \< .001, two‐sided ANCOVA as specified in the protocol) ([Table S2](#dom13079-supitem-0001){ref-type="supplementary-material"}, [Appendix S1](#dom13079-supitem-0001){ref-type="supplementary-material"}). As illustrated in Figure [1](#dom13079-fig-0001){ref-type="fig"}, HbA1c started to decrease within 4 weeks of treatment in the C + T group and continued to decrease through to Week 12, and the reduction was sustained until the end of treatment. By contrast, HbA1c remained broadly unchanged in the C + P group. Significantly greater proportions of patients in the C + T group than in the C + P group achieved HbA1c \<7.0% (50.00% vs 8.11%, respectively; *P* \< .001) or \<8.0% (75.76% vs 18.42%, respectively; *P* \< .001, 2‐sided Fisher\'s exact test as specified in the protocol) at Week 24 (LOCF).

![Changes in HbA1c from baseline to each visit during the 24‐week treatment period, and at the last observation carried forward. Values are expressed as the least squares mean ± standard error. The least squares mean was determined by analysis of covariance with treatment group as a fixed factor and the baseline value as a covariate. \**P* \< .001 for the C + T group vs C + P group at all time points. C + P, canagliflozin plus placebo; C + T, canagliflozin plus teneligliptin; HbA1c, glycated haemoglobin; LOCF, last observation carried forward; LS mean, least squares mean](DOM-20-453-g001){#dom13079-fig-0001}

[Table S2](#dom13079-supitem-0001){ref-type="supplementary-material"} ([Appendix S1](#dom13079-supitem-0001){ref-type="supplementary-material"}) shows the changes in other efficacy endpoints from baseline to Week 24 (LOCF). Supporting the change in HbA1c, the reduction in FPG was significantly greater in the C + T group, with a between‐group difference of −15.6 ± 3.9 mg/dL (LS mean ± SE, *P* \< .001, two‐sided ANCOVA \[baseline value as covariate\] as specified in the protocol). The absolute and percent changes in body weight were 0.11 ± 0.20 kg and 0.09% ± 0.29%, respectively, in the C + T group vs −0.98 ± 0.20 kg and −1.34% ± 0.29%, respectively, in the C + P group. The between‐group differences in changes in body weight were 1.09 ± 0.29 kg and 1.43% ± 0.41% (both *P* \< .001), respectively. Additional efficacy results and the results of a mixed‐meal tolerance test are included in [Appendix S1](#dom13079-supitem-0001){ref-type="supplementary-material"} (Results).

3.3. Safety {#dom13079-sec-0009}
-----------

Table [1](#dom13079-tbl-0001){ref-type="table-wrap"} shows the incidence of AEs, including AEs of special interest in both groups. AEs and drug‐related AEs occurred in 49.4% and 14.3% of patients, respectively, in the C + P group and in 55.8% and 6.5% of patients, respectively, in the C + T group. Serious AEs occurred in 2.6% and 1.3% of patients in the C + P and C + T groups, respectively. There were no serious drug‐related AEs in either group. AEs led to discontinuation and drug‐related AEs led to discontinuation in 3.9% and 1.3% of patients, respectively, in the C + P group. There were no AEs leading to treatment discontinuation in the C + T group. In terms of AEs of special interest, there were no episodes of hypoglycaemia in either group. Gastrointestinal disorders (11.7% vs 7.8%) and skin and subcutaneous tissue disorders (10.4% vs 5.2%) were more common in the C + T group than in the C + P group. Malignant neoplasms occurred in 2.6% of patients in the C + P group and in no patients in the C + T group. Other AEs of clinical relevance occurred in ≤2 patients in each group.

###### 

Adverse events

                                                C + P   C + T                                               
  --------------------------------------------- ------- ---------------------------------------------- ---- --------
  AEs                                           38      (49.4)                                         43   (55.8)
  Drug‐related AEs                              11      (14.3)                                         5    (6.5)
  Serious AEs                                   2       (2.6)                                          1    (1.3)
  Serious drug‐related AEs                      0       (0.0)                                          0    (0.0)
  AEs leading to discontinuation                3       (3.9)                                          0    (0.0)
  Drug‐related AEs leading to discontinuation   1       (1.3)                                          0    (0.0)
  AEs of special interest                                                                                   
  Hypoglycaemia                                 0       (0.0)                                          0    (0.0)
  Osmotic diuresis                              1       (1.3)                                          1    (1.3)
  Volume depletion                              0       (0.0)                                          1    (1.3)
  Vulvovaginal candidiasis                      1       (5.3)[a](#dom13079-note-0003){ref-type="fn"}   0    (0.0)
  Urinary tract infection                       1       (1.3)                                          0    (0.0)
  Blood ketone bodies increased                 2       (2.6)                                          1    (1.3)
  Hepatic function impairment                   2       (2.6)                                          2    (2.6)
  Skin and subcutaneous tissue disorders        4       (5.2)                                          8    (10.4)
  Cardiovascular‐related events                 0       (0.0)                                          1    (1.3)
  Malignant neoplasm                            2       (2.6)                                          0    (0.0)
  Gastrointestinal disorders                    6       (7.8)                                          9    (11.7)

Abbreviations: C + P, canagliflozin plus placebo; C + T, canagliflozin plus teneligliptin; AE, adverse event.

In females only (n = 19).

4. DISCUSSION {#dom13079-sec-0010}
=============

This randomized, placebo‐controlled, double‐blind, multicentre trial examined the efficacy and safety of teneligliptin or placebo added to canagliflozin therapy for 24 weeks in Japanese patients with inadequately controlled T2DM. Teneligliptin was associated with significant improvements in glycaemic control, including HbA1c, FPG and postprandial plasma glucose, compared with placebo. Moreover, greater proportions of patients in the C + T group achieved HbA1c \<7.0% or \<8.0%. These improvements were consistent with those observed in earlier clinical trials in which teneligliptin was added to oral hypoglycaemic drugs other than SGLT2 inhibitors.[14](#dom13079-bib-0014){ref-type="ref"}, [15](#dom13079-bib-0015){ref-type="ref"}, [16](#dom13079-bib-0016){ref-type="ref"} In fasting conditions, the fasting proinsulin/C‐peptide ratio was reduced and HOMA2‐%B was increased in the C + T group compared with the C + P group. In addition, in mixed‐meal tolerance tests, there were reductions in the changes from baseline in postprandial plasma glucose, as well as increases in the change from baseline in C‐peptide AUC~0‐2h~ and the C‐peptide AUC~0‐2hours~/plasma glucose AUC~0‐2hours~ in the C + T group compared with the C + P group.

These findings seem reasonable considering the mechanism of action of DPP‐4 inhibitors, which promote insulin secretion in a glucose concentration‐dependent manner.[1](#dom13079-bib-0001){ref-type="ref"} Taken together, these results support our hypothesis that teneligliptin added to ongoing canagliflozin therapy is beneficial in terms of improving glycaemic control in patients with inadequately controlled T2DM, because of their complementary but independent mechanisms of action.

Additionally, the use of canagliflozin and teneligliptin in combination is considered to have the following benefits. First, the attenuation of β‐cell burden by the SGLT2 inhibitor may lead to enhanced incretin‐stimulated insulin secretion. Second, because canagliflozin increases total GLP‐1 after meals,[17](#dom13079-bib-0017){ref-type="ref"} teneligliptin add‐on therapy may increase the level of active GLP‐1.

In this trial, the change in body weight from baseline to Week 24 was −0.98 kg in the C + P group and 0.11 kg in the C + T group. The change in urinary glucose/creatinine ratio from baseline was lower in the C + T group compared with the C + P group, probably because of the glucose‐lowering effect of teneligliptin. This result suggests that calorie loss through glucose excretion was lower in the C + T group than in the C + P group throughout the treatment period. Furthermore, some meta‐analyses and clinical trials of teneligliptin have reported that DPP‐4 inhibitors negligibly increase body weight, probably as a result of enhanced insulin‐stimulated glucose uptake.[15](#dom13079-bib-0015){ref-type="ref"}, [16](#dom13079-bib-0016){ref-type="ref"}, [18](#dom13079-bib-0018){ref-type="ref"}, [19](#dom13079-bib-0019){ref-type="ref"}, [20](#dom13079-bib-0020){ref-type="ref"}

The present trial also examined the safety of teneligliptin added to ongoing canagliflozin therapy. Of note, there were no serious drug‐related AEs or deaths. Moreover, no episodes of hypoglycaemia were detected. AEs related to osmotic diuresis, volume depletion, increased serum ketone bodies, hepatic function impairment, skin disorders, cardiovascular disorders and gastrointestinal disorders were observed in the C + T group. Although skin disorders and gastrointestinal disorders were slightly more frequent in the C + T group, only one skin disorder (eczema) and one gastrointestinal disorder (constipation) were considered to be drug‐related in the C + T group. These classes of AEs have already been reported for teneligliptin or canagliflozin, and there were no additional safety concerns. Overall, these findings suggest that teneligliptin added to canagliflozin therapy is likely to be well tolerated in clinical practice.

We previously reported that canagliflozin added to teneligliptin monotherapy in Japanese patients with poorly controlled T2DM was effective and well tolerated.[11](#dom13079-bib-0011){ref-type="ref"}, [12](#dom13079-bib-0012){ref-type="ref"} Taken together with the results of the present trial, this suggests that the fixed‐dose combination of teneligliptin and canagliflozin may be a beneficial treatment option.

Some limitations of this study warrant mention. In particular, we enrolled only Japanese patients. However, data on the use of this drug combination in Japanese patients are important, particularly when we consider the differences in pathophysiology between Japanese and non‐Japanese patients.[13](#dom13079-bib-0013){ref-type="ref"} Longer studies may be needed to verify the current findings obtained over 24 weeks.

In conclusion, this trial showed that teneligliptin added to ongoing canagliflozin therapy was effective in terms of improving glycaemic control and was well tolerated in Japanese patients with inadequately controlled T2DM.
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**Figure S2.** Patient disposition and reasons for discontinuation.

###### 

Click here for additional data file.

###### 

**Figure S3.** Changes in urinary glucose/creatinine ratio (A) and total serum ketone bodies (B) from baseline to each visit in the 24‐week treatment period.
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